AbCellera Biologics Inc.
Rating
Updated: Aug 22, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems ...
Latest News
5 days ago · businesswire.com
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
28 days ago · benzinga.com
What'sGoing On With AbCellera Biologics Stock On Tuesday?AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
1 month ago · seekingalpha.com
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say YesBiotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
1 month ago · businesswire.com
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsVANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
1 month ago · benzinga.com
What's Going on With AbCellera Biologics Stock On Wednesday?AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
1 month ago · businesswire.com
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsVANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
1 month ago · defenseworld.net
Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 16,666 call options on the company. This is an increase of approximately 151% compared to the typical daily volume of 6,636 call options. AbCellera Biologics News Roundup Here are the key news stories impacting
1 month ago · seekingalpha.com
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes TranscriptAbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
1 month ago · benzinga.com
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
1 month ago · gurufocus.com
AbCellera Stock Jumps 33% on a Positive Menopause TrialAbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experimental menopause drug ABCL635 met both primary goals in a Ph
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ABCL